FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

U.S. International Trade Commission Will Probe South Korean Drugmaker

March 12, 2019
A A

The U.S. International Trade Commission (USITC) will open an investigation into Daewoong Pharmaceuticals’ botulinum toxin products, which are marketed under brand names like Nabota and Jeuveau.

The investigation centers around a complaint filed by Allergan and its partner Medytox, alleging that Daewoong misappropriated trade secrets to create its botox products.

Allergan and Medytox called on the USITC to issue a cease-and-desist order to the South Korean manufacturer. The case will be assigned to a commission judge who will hold an evidentiary hearing.

View today's stories